STRATA Skin Sciences Inc
NASDAQ: SSKN · HEALTHCARE · MEDICAL DEVICES
Updated 2026-06-05
STRATA Skin Sciences Inc (SSKN) Financial statements
SEC filings — annual and quarterly data.
Margin trends — annual
| Year | Revenue | Net income | Gross margin | Op. margin | Profit margin |
|---|---|---|---|---|---|
| 2006 | — | $-10.59M | — | — | — |
| 2007 | — | $-11.94M | — | — | — |
| 2008 | $10000.00 | $-17.61M | — | -182,741.97% | -176,050.31% |
| 2009 | — | $-18.45M | — | — | — |
| 2010 | — | $-19.92M | — | — | — |
| 2011 | $0.00 | $-20.38M | — | — | — |
| 2012 | $278461.00 | $-22.67M | -633.44% | -8,160.77% | -8,142.25% |
| 2013 | $536000.00 | $-25.95M | -709.89% | -4,502.61% | -4,841.04% |
| 2014 | $915000.00 | $-16.03M | -439.34% | -1,816.61% | -1,752.13% |
| 2015 | $18.50M | $-27.91M | 25.82% | -89.08% | -150.90% |
| 2016 | $31.76M | $-3.33M | 60.21% | -11.33% | -10.50% |
| 2017 | $31.45M | $-21.51M | 57.08% | -7.66% | -68.41% |
| 2018 | $29.86M | $-4.03M | 57.34% | -11.24% | -13.51% |
| 2019 | $31.59M | $-3.79M | 64.17% | -9.53% | -12.00% |
| 2020 | $23.09M | $-4.41M | 61.21% | -17.65% | -19.11% |
| 2021 | $29.98M | $-2.71M | 66.22% | -14.68% | -9.03% |
| 2022 | $36.16M | $-5.55M | 60.20% | -12.86% | -15.35% |
| 2023 | $33.36M | $-10.83M | 55.34% | -25.79% | -32.47% |
| 2024 | $33.56M | $-10.09M | 56.85% | -27.58% | -30.05% |
| 2025 | $30.70M | $-6.26M | 58.25% | -19.01% | -20.40% |
Frequently asked questions
What is STRATA Skin Sciences Inc's revenue?
STRATA Skin Sciences Inc's trailing twelve-month revenue is $30.70M. Revenue is the top line the whole model builds on, and at this scale the question shifts from how fast it grows to whether margins hold as it compounds.
How profitable is SSKN?
In its most recent fiscal year, SSKN ran a gross margin of 58.25%, an operating margin of -19.01%, and a net margin of -20.40%. Margins this high mean most of each extra dollar of revenue drops through to profit, which is the signature of real pricing power.
How much free cash flow does SSKN generate?
SSKN produced $-4.26M in free cash flow in its most recent fiscal year. Free cash flow is what is left after running and reinvesting in the business, and it is the cash that actually funds buybacks, dividends, and a stronger balance sheet.